Home > Pressrelease > Continuous Renal Replacement Therapy Market size to exceed USD 1.4bn by 2025

Continuous Renal Replacement Therapy Market size to exceed USD 1.4bn by 2025

  • Published Date: August 22, 2019

Continuous Renal Replacement Therapy Market size is set to exceed USD 1.4 billion by 2025; according to a new research report by Global Market Insights Inc.

Increasing prevalence of renal diseases will propel the continuous renal replacement therapy market growth during analysis timeframe. According to Kidney Disease Statistics, an estimated 31 million people suffer from chronic kidney disease in the U.S. alone. Similarly, the number of individuals experiencing pain due to kidney diseases is significantly high in developing regions. Doctors and physicians recommend CRRT for managing the pain caused due to chronic kidney diseases. Thus, mounting adoption of CRRT for treating chronic diseases should stimulate the market growth.

Rising geriatric population should positively impact the market growth. Elderly population suffering from diabetes and other chronic conditions makes them susceptible to kidney failure. According to World Population Review, around 26.7% of the population in Japan consists of people in the age group of 65 years and above. Majority of the elderly population suffers from acute kidney failure surges the demand for continuous renal replacement therapy that should boost the industry growth. However, complications associated with the continuous renal replacement therapy may restrain industry growth to some extent.

Continuous Renal Replacement Therapy Market

Get more details on this report - Request Free Sample PDF

Slow Continuous Ultrafiltration (SCUF) segment of continuous renal replacement therapy market will witness around 4% growth during the forecast timeframe. SCUF is mostly preferred by patients experiencing blood pressure problems and cardiac failure. Cardiovascular diseases may interfere with normal kidney functioning and result in partial or total loss of kidney functions. In such chronic conditions, there is an electrolyte imbalance.  There is a considerable reduction in the blood urea and creatinine levels after undergoing continuous slow ultrafiltration treatment that stimulates its demand. Moreover, slow continuous ultrafiltration is known to reduce extravascular water and has significantly reduced the mortality rates in patients suffering from acute decompensated heart failure that should further propel the segmental growth.

Instruments segment accounted for over 39% in 2018 and is will grow considerably over forthcoming years. Industry players are involved in developing superior quality instruments that are utilized in CRRT. For instance, in September 2017, Baxter International announced about its commercial launch of oXiris set, used be used in continuous renal replacement therapy (CRRT). oXiris set helps in removing excessive levels of endotoxin, cytokines from a patient’s blood. Hence, growing availability of advanced CRRT instruments should stimulate the segmental growth.

Renal therapies segment market was valued over USD 690 million in 2018. Increasing prevalence of kidney diseases should escalate the demand for renal therapies. Newly developed renal therapies are usually used in treating rapidly rising serum, creatinine levels, oliguria and severe metabolic acidosis. Therefore, these renal therapies are highly preferred by people suffering from end-stage kidney failure diseases that do not find donors for kidney transplant stimulates the business growth.

Browse key industry insights spread across 160 pages with 98 market data tables & 8 figures & charts from the report, “Continuous Renal Replacement Therapy Market Size By Modality (Continuous Venovenous Hemofiltration, Continuous Venovenous Hemodiafiltration, Continuous Venovenous Hemodialysis, Slow Continuous Ultrafiltration), By Product (Instruments, Consumables), By Therapy (Renal, Non-renal) Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019 – 2025” in detail along with the table of contents:

Asia Pacific continuous renal replacement therapy market held around 19.5% revenue share in 2018. Regional growth will be driven by the increasing prevalence of diabetes in emerging economies such as India and China. These countries have unhealthy eating habit and sedentary lifestyle that leads to obesity in individuals ultimately increasing the blood sugar levels. Diabetes interferes with normal kidney functioning and is a leading cause of renal failure in geriatric population. Moreover, CRRT system manufacturing companies based in Asia Pacific such as Asahi Kasei focus their R&D efforts on developing new CRRT systems that provide accurate treatment to patients suffering from acute renal injuries. Aforementioned factors coupled with rising government initiatives will positively impact the continuous renal replacement therapy market in Asia Pacific.

Players operational in the continuous renal replacement therapy market include Asahi Kasei Corporation, B.Braun Melsungen, Baxter International, Fresenius Medical Care, Infomed, Medica, Medical Components, Medites, Medtronic, Nikkiso, Nxtstage, Toray. The companies underatke certain strategic initiatives such as new product launch, acquisitions and mergers that help them in maintaining their market position. For instance, in September 2017, B. Braun launched xevonta, a next generation dialyzer. Its advanced membrane technology helps in removing toxins from patient's blood. The new product launch will help in broadening its product portfolio.

Continuous renal replacement therapy market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2014 to 2025, for the following segments:

Continuous Renal Replacement Therapy Market, By Modality (USD Million)

  • Continuous Venovenous Hemofiltration (CVVH) 
  • Continuous Venovenous Hemodiafiltration (CVVHDF) 
  • Continuous Venovenous Hemodialysis (CVVHD) 
  • Slow Continuous Ultrafiltration (SCUF)

By Product (USD million)

  • Instruments 
  • Consumables 

By Therapy (USD million)

  • Renal 
  • Non-renal

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Russia
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East Asia & Africa
    • Saudi Arabia
    • South Africa
    • UAE


Authors: Sumant Ugalmugle